Search
Protalix Biotherapeutics Inc
PLXAdd to Watchlist
2.395USD
+0.025+1.05%
Close 07-27 16:00（ET）Quotes delayed by 15 min
192.97MMarket Cap
12.40P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of Protalix Biotherapeutics Inc is 8.00, ranking 56 out of 155 in the Pharmaceuticals industry. The average price target is 12.50, with a high of 13.00 and a low of 12.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
11.000
Target Price
+364.14%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Protalix Biotherapeutics Inc
PLX
1
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Protalix Biotherapeutics Inc's expected revenue for the next quarter?
Protalix Biotherapeutics Inc's expected revenue is 12.93M.
What is Protalix Biotherapeutics Inc's price target?
Analysts forecast that Protalix Biotherapeutics Inc's price target is USD 12.50, with the highest forecast at USD 13.00 and the lowest forecast at USD 12.00.
How have Protalix Biotherapeutics IncPLX's recent earnings per share performed?
The market expectation was USD 0.23, while Protalix Biotherapeutics IncPLX's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.01.
What is the analyst rating for Protalix Biotherapeutics Inc?
Based on the ratings of Protalix Biotherapeutics Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.